Business Advisors

Chief Strategy Officer, CAVALLO (previously Sales Pad)
Grand Rapids, Michigan

Matt Abbott is a member of MAX BioPharma’s Business Advisory Board. Matt has two decades of experience advising companies across a range of business issues, including growth strategies, digital marketing, M&A, organization, pricing, cost reduction, complexity reduction and change management. Matt has served clients in North America, Asia and Europe. Matt was a Partner at Bain & Company in Los Angeles for 5 years before transitioning to an independent consultant. Prior to joining Bain, Matt was a Senior Manager with Deloitte Consulting. Matt has served as an informal advisor to MAX BioPharma since inception and was instrumental in driving initial business plan development activities. Matt has a Bachelor of Science degree in Mechanical Engineering from the University of Michigan and Master of Business Administration degree from the UCLA Anderson School of Management.

Chair, Intellectual Property and Technology Transactions Practice Group
Stubbs Alderton & Markiles, LLP

Kevin DeBré is a member of MAX BioPharma’s Business Advisory Board. He is currently a partner at Stubbs Alderton & Markiles, LLP. As a business lawyer, a registered patent lawyer and a former engineer, and with his particular expertise in structuring and negotiating intellectual property-driven deals, Kevin has been an advisor to entrepreneurs and companies engaged in building businesses based on technology or intellectual property assets including software companies, e-commerce enterprises, media companies, medical device manufacturers, and life science start ups. He is frequently a speaker at conferences on technology commercialization and intellectual property licensing, and is the author of “Licensing of Trade Secrets and Know-How” in Trade Secret Litigation and Protection in California, an attorney’s practice book published by the State Bar of California, and a contributing author of “Joint Ventures and Strategic Alliances”, in Intellectual Property in Business Transactions, an attorney’s practice book published by Continuing Education of the Bar. Prior to joining Stubbs Alderon & Markiles, LLP, Kevin was a partner at the international law firm, Brobeck Phleger & Harrison, LLP, where he headed the firm’s technology transactions practice in Southern California. Kevin received his B.S. degree from the University of California, Davis, and his J.D. from Hastings College of the Law.

President & CEO, PhageNova Bio
Los Angeles, California

Jason Rifkin is a member of MAX BioPharma’s Business Advisory Board. Jason is currently President & CEO of PhageNova Bio. As a biotechnology and medical device executive with extensive experience in developmental stage life sciences companies. Jason has managed all aspects of company operations including clinical operations, business development, technology licensing and capital raising. Jason also serves as President of PreScience Labs, an early stage oncology company where he oversees the build-up of a Phase I clinical trial program. Prior to joining PreScience, Jason held a number of executive positions in which he oversaw the transition of Delcath Systems – a specialty pharmaceutical and medical device company focused on oncology — from a developmental stage company to a publicly traded commercial operation. Before joining Delcath, he practiced law with Fox Rothschild, serving as an associate in the Corporate Department-Pharmaceuticals and Biotechnology Group. Jason received a Bachelor’s Degree from The University of Pennsylvania, a Law Degree from Northeastern University School of Law and a Masters of Biotechnology from The University of Pennsylvania, School of Engineering and Applied Sciences